GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (STU:VM4) » Definitions » Price-to-Funds-From-Operations

Vanda Pharmaceuticals (STU:VM4) Price-to-Funds-From-Operations : (As of Mar. 31, 2025)


View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Vanda Pharmaceuticals Business Description

Traded in Other Exchanges
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.